Literature DB >> 29233557

BGJ398 for FGFR-altered advanced cholangiocarcinoma.

Judith A Gilbert.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29233557     DOI: 10.1016/S1470-2045(17)30902-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  7 in total

1.  FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer.

Authors:  Ying Yang; Tingting Lu; Ziming Li; Shun Lu
Journal:  Cell Adh Migr       Date:  2020-12       Impact factor: 3.405

2.  The Autocrine FGF/FGFR System in both Skin and Uveal Melanoma: FGF Trapping as a Possible Therapeutic Approach.

Authors:  Sara Rezzola; Roberto Ronca; Alessandra Loda; Mohd Imtiaz Nawaz; Chiara Tobia; Giuseppe Paganini; Federica Maccarinelli; Arianna Giacomini; Francesco Semeraro; Marco Mor; Marco Presta
Journal:  Cancers (Basel)       Date:  2019-09-04       Impact factor: 6.639

3.  Preoperative risk grade predicts the long-term prognosis of intrahepatic cholangiocarcinoma: a retrospective cohort analysis.

Authors:  Jianping Zhao; Yao Chen; Jingjing Wang; Jian Wang; Ying Wang; Songshan Chai; Yuxin Zhang; Xiaoping Chen; Wanguang Zhang
Journal:  BMC Surg       Date:  2021-03-06       Impact factor: 2.102

4.  Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma.

Authors:  Asmerom T Sengal; Deborah Smith; Cameron E Snell; Samuel Leung; Aline Talhouk; Elizabeth D Williams; Jessica N McAlpine; Pamela M Pollock
Journal:  J Pathol Clin Res       Date:  2022-07-22

Review 5.  Emerging role of precision medicine in biliary tract cancers.

Authors:  James M Bogenberger; Thomas T DeLeon; Mansi Arora; Daniel H Ahn; Mitesh J Borad
Journal:  NPJ Precis Oncol       Date:  2018-10-03

Review 6.  Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma.

Authors:  Raluca Maria Fostea; Elisa Fontana; Gonzalo Torga; Hendrik-Tobias Arkenau
Journal:  Cancers (Basel)       Date:  2020-09-11       Impact factor: 6.639

7.  Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors.

Authors:  Tianyu Wu; Xiaoqing Jiang; Xin Zhang; Bodeng Wu; Bin Xu; Xiaoliu Liu; Lei Zheng; Yu Wang
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.